Inhibitory effects of a novel aromatase inhibitor, YM511, on growth of endometrial explants and insulin-like growth factor-I gene expression in rats with experimental endometriosis

Journal of Steroid Biochemistry and Molecular Biology

Volumn 63, Issue 1-3, 1997, Pages 75-80

  Kudoh, Masafumi ^a   Susaki, Yoko ^a   Ideyama, Yukitaka ^a   Nanya, Taiki ^a   Mori, Masamichi ^a   Shikama, Hisataka ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 [N (4 BROMOBENZYL) N (1,2,4 TRIAZOL 4 YL)AMINO]BENZONITRILE; AROMATASE; AROMATASE INHIBITOR; ESTROGEN; MESSENGER RNA; SOMATOMEDIN C;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENDOMETRIOSIS; ENDOMETRIUM; ENZYME INHIBITION; FEMALE; GENE EXPRESSION REGULATION; NONHUMAN; RAT;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; ENDOMETRIOSIS; ENDOMETRIUM; ENZYME INHIBITORS; FEMALE; GENE EXPRESSION; INSULIN-LIKE GROWTH FACTOR I; LEUPROLIDE; OVARIECTOMY; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; TRIAZOLES; UTERUS;

ANIMALIA;

EID: 0031443052     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-0760(97)00074-5     Document Type: Article

References (31)

1. Gerbie A. B. and Merrill J. A., Pathology of endometriosis. Clin. Obstet. Gynecol. 31 (1988) 779-786.
2. Barbieri R. L., Evans S. and Kistner R. W., Danazol in the treatment of endometriosis: analysis of 100 cases with a 4 year follow up. Fertil. Steril. 31 (1982) 737-746.
3. Henzl M. R., Corson S. L., Moghissi K., Buttram V. C., Berqvist C. and Jacobson J., Administration of nasal nafarelin as compared with oral danazol for endometriosis - a multicenter double-blind comparative clinical trial. N. Engl. J. Med. 318 (1988) 485-489.
4. Barbieri R. L., Endometriosis 1990. Current treatment approaches. Drugs 39 (1990) 502-510.
5. Murphy L. J. and Friesen H. G., Differential effects of estrogen and growth hormone on uterine and hepatic insulin-like growth factor I gene expression in the ovariectomized hypophysectomized rat. Endocrinology 122 (1988) 325-332.
6. Huet-Hudson Y. M., Chakraborty C., De S. K., Suzuki Y., Andrews G. K. and Dey S. K., Estrogen regulates the synthesis of epidermal growth factor in mouse uterine epithelial cells. Mol. Endocrinol 4 (1990) 510-523.
7. Das S. K., Flanders K. C., Andrews G. K. and Dey S. K., Expression of transforming growth factor-ßisoforms (β2 and β3) in the mouse uterus: Analysis of the periimplantation period and effects of ovarian steroids. Endocrinology 130 (1992) 3459-3466.
8. Daughaday W. H, and Rotwein P., Insulin-like growth factors I and II. Peptide, messenger ribonucleic acid, and gene structures, serum, and tissue concentrations. Endocr. Rev. 10 (1989) 68-91.
9. Brodie A. M. H., Schwarzel W. C. and Brodie H. J., Studies on the mechanism of estrogen biosynthesis in rat ovary-I. J. Steroid. Biochem. 7 (1976) 787-793.
10. Longcope C., Pratr J. H., Schneider S. H. and Fineberg S. E., Aromatization of androgens by muscle and adipose tissues in vivo.J. Clin. Endocrinol Metab. 46 (1978) 146-152.
11. Noble L. S., Simpson E. R., Johns A. and Bulun S. E., Aromatase expression in endometriosis. J. Clin. Endocrinol. Metab. 81 (1996) 174-179.
12. Kudoh M., Susaki Y., Ideyama Y., Nanya T., Okada M., Shikama H. and Fujikura T., The potent and selective inhibition of estrogen production by non-steroidal aromatase inhibitor, YM511. J. Steroid. Biochem. Molec. Biol. 54 (1995) 265-271.
13. Kudoh M., Susaki Y., Ideyama Y., Nanya T., Mori M., Shikama H. and Fujikura T., Inhibitory effect of a novel non-steroidal aromatase inhibitor, YM511 on the proliferation of MCF-7 human breast cancer cell. J. Steroid. Biochem. Molec. Biol. 58 (1996) 189-194.
14. Jones R. C., The effect of a luteinizing hormone releasing hormone (LRH) agonist (Wy-40,972), levonorgestrel, danazol and ovariectomy on experimental endometriosis in the rat. Acta Endocrinol. 106 (1984) 282-288.
15. Sakata M., Terakawa N., Mizutani T., Tanizawa O., Matsumoto K., Terada N. and Sudo K., Effects of danazol, gonadotropin-releasing hormone agonist, and a combination of danazol and gonodotropin-releasing hormone agonist on experimental endometriosis. Am. J. Obstet. Gynecol. 163 (1990) 1679-1684.
16. Sakura Y., Masaki T., Sudo K., Nomura M. and Shino A., Histological studies on the therapeutic effect of sustained-release microspheres of a potent LHRH agonist in an experimental endometriosis model in rats. Endocrinol. Japon. 37 (1990) 719-729.
17. Okada H., Heya T., Ogawa Y. and Shimamoto T., One-month release injectable microcapsules of a luteinizing hormonereleasing hormone agonist (leuprolide acetate) for treating experimental endometriosis in rats. J. Pharmacol. Exp. Ther. 244 (1988) 744-750.
18. Chomczynski P. and Sacchi N., Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162 (1987) 156-159.
19. Ausubel, F. M., Brent, R., Kingston, R. E., Moore, D. D., Seidman, J. G., Smith, J. A. and Struhl, K., Current protocols I molecular biology. Green and Wiley-Interscience, New York, 1989.
20. Möller C., Arner P., Sonnenfeld T. and Norstedt G., Quantitative comparison of insulin-like growth factor mRNA levels in human and rat tissues analyzed by a solution hybridization assay. J. Mol. Endocr. 7 (1991) 213-222.
21. Schenken R. S. and Asch R. H., Surgical induction of endometoriosis in the rabbit: effects on fertility and concentrations of peritoneal fluid prostaglandins. Fertil. Steril. 34 (1980) 581-587.
22. Jones R. C., Cohen M. and Bell J., Local progestational effect of norgestrel in an intrauterine silastic capsule. Contraception 8 (1973) 439-449.
23. Hazum E. and Conn P. M., Molecular mechanism of gonadotropin releasing hormone (GnRH) action. I. the GnRH receptor. Endocr. Rev. 9 (1988) 379-386.
24. Tjaden B., Galetto D., Woodruff J. D. and Rock J. A., Time-related effects of RU486 treatment in experimentally induced endometriosis in the rat. Fertil Steril. 59 (1993) 437-440.
25. Huynh H. T. and Pollak M., Insulin-like growth factor I gene expression in the uterus is stimulated by tamoxifen and inhibited by pure antiestrogen ICI 182780. Cancer Res. 53 (1993) 5585-5588.
26. Murphy L. J., Bell G. I. and Friesen H. G., Tissue distribution of Insulin-like growth factor I and II messenger ribonucleic acid in the adult rat. Endocrinology 120 (1987) 1279-1282.
27. Rom W. N., Basset P., Fells G. A., Nukiwa T., Trapnell B. C. and Crystal R. G., Alveolar macrophages release an insulin-like growth factor I-type molecule. J. Clin. Invest. 82 (1988) 1685-1693.
28. Baxter J. B., Blalock J. E. and Weigent D. A., Characterization of immunoreactive insulin-like growth factor-I from leukocytes and its regulation by growth hormone. Endocrinology 129 (1991) 1727-1734.
29. Barbieri R. L., Hormone treatment of endometriosis: the estrogen threshold hypothesis. Am. J. Obstet. Gynecol. 166 (1992) 740-745.
30. Friedman A. J. and Hornstein M. D., Gonadotropin-releasing hormone agonist plus estrogen-progestin 'add-back' therapy for endometriosis-related pelvic pain. Fretil. Steril. 60 (1993) 236-241.
31. Adashi E. Y., Long-term gonadotropin releasing hormone agonist therapy: the evolving issue of steroidal 'add-back' paradigms. Hum. Reprod. 9 (1994) 1380-1397.